17:53 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; gastric cancer; lung cancer; brain cancer In vitro, cell culture and mouse studies identified four methylquinazoline-based PI3K inhibitors that could help treat cancer. Chemical synthesis of methylquinazoline analogs and in vitro enzyme activity assays...
18:21 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest CAR T cells targeting MCSP could help treat glioblastoma. In tumor samples from patients, high MCSP expression was correlated with poor overall survival. In a...
21:05 , Jul 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, in vitro, cell culture and mouse studies identified a benzamide-based CSNK1A activator that could help treat Wnt signaling-driven colorectal cancer. In colorectal cancer patients, low tumor levels of CSNK1A were associated...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Abzena, Alpha Cancer deal

Abzena's PolyTherics Ltd. subsidiary partnered with Alpha Cancer to develop drug conjugates to treat cancer. PolyTherics will use its ThioBridge linker technology to attach an undisclosed cytotoxic drug to Alpha Cancer's recombinant human ...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Alpha Cancer, Bradmer deal

The companies signed a letter of intent to combine businesses through a reverse merger with the newco to be named Alpha Cancer Technologies Inc. The close is subject to Alpha Cancer completing a private placement...
07:00 , Jun 28, 2004 |  BC Week In Review  |  Company News

Biocon, CIMAB deal

Biocon Ltd. (NSE:BIOCONEQ), Bangalore, India   CIMAB S.A., Havana, Cuba   Business: Cancer, Autoimmune, Transplantation   The parties' Biocon Biopharmaceuticals JV received a license to five compounds from CIMAB, the commercial branch of the Centre of Molecular...
07:00 , Jun 22, 2004 |  BC Extra  |  Company News

Biocon, CIMAB expand JV

Biocon Biopharmaceuticals, a joint venture between Biocon (NSE:BIOCONEQ) and CIMAB (Havana, Cuba), has licensed five compounds from CIMAB. These include: h-T1, a humanized monoclonal antibody against CD6 to treat T cell lymphoma, rheumatoid arthritis (RA)...
07:00 , Jun 21, 2004 |  BC Week In Review  |  Clinical News

Thyrogen thyrotropin alpha cancer data

In an international study comparing Thyrogen plus thyroid hormone to withdrawal of thyroid hormone in 63 patients who had undergone thyroidectomy, all patients were successfully ablated in both treatment groups, the primary endpoint. Billewicz hypothyroidism...